• Comerica CMA has plans to purchase Sterling Bancshares SBIB for $1.03 billion for a deal worth $10 per share
• GlaxoSmithKline GSK reported charges of $3.4 billion in the fourth quarter to settle lawsuits and fines from earlier sales practices, mostly because of its diabetes drug Avandia
• Boeing BA reported a resumption of certified testing of its long-delayed 787 Dreamliner on Monday, almost three years behind its expected schedule
• Delta Airlines DAL has reported airlines earnings numbers, with a fourth quarter showing of $0.19, below the Zacks Consensus Estimate of $0.26, on revenues of $7.8 billion ahead of the Zacks Consensus Estimate of $7.687 billion
• According to Piper Jaffray PJC, weakness in Apple's AAPL shares due to absence of CEO Steve Jobs' because of health related issues offers a fantastic buying opportunity in the shares
• FBR maintained an "outperform" rating on JP Morgan JPM, raising the target price to $53 from $45
• Citigroup C reported fourth quarter earnings of $0.04, lower than the Zacks Consensus Estimates of $0.08 but reversing last year's loss of $0.33, on revenues of $19.5 billion, below the Zacks Consensus Estimate of $20.484 billion
• Goldman Sachs GS has downgraded Humana HUM to "sell" from "neutral" rating with a target price of $56
• Deutsche Bank DB has upgraded Symantec SYMC to "buy" from "hold" rating raising its target price to $22 from $19
APPLE INC (AAPL): Free Stock Analysis Report
BOEING CO (BA): Free Stock Analysis Report
CITIGROUP INC (C): Free Stock Analysis Report
COMERICA INC (CMA): Free Stock Analysis Report
DELTA AIR LINES (DAL): Free Stock Analysis Report
DEUTSCHE BK AG (DB): Free Stock Analysis Report
GOLDMAN SACHS (GS): Free Stock Analysis Report
GLAXOSMITHKLINE (GSK): Free Stock Analysis Report
HUMANA INC NEW (HUM): Free Stock Analysis Report
JPMORGAN CHASE (JPM): Free Stock Analysis Report
PIPER JAFFRAY (PJC): Free Stock Analysis Report
STERLING BCS-TX (SBIB): Free Stock Analysis Report
SYMANTEC CORP (SYMC): Free Stock Analysis Report
Zacks Investment Research
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.